Profile change history

What changed for Glatiramer acetate?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Glatiramer acetate identity.

65Total events
65Record additions
0Version changes
16Cited source years

Collection chronology

Evidence added to PeptideScanner

Browse all 65 connected records →

Showing the latest 65 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 17, 2026.

Record added

ClinicalTrials.gov record NCT05344469

PeptideScanner retained ClinicalTrials.gov record NCT05344469 at 2026-11-17T13:28:01.467Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 17, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Record added

Federal Register proposed rule 2015-32246

The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.

PeptideScanner change date
November 17, 2026
Cited source date
December 23, 2015
Evidence lane
Regulatory
Record added

Federal Register notice 2016-08682

The Federal Register published notice 2016-08682, attributed to FDA and its parent HHS department, on 2016-04-15. Its official title is “Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.

PeptideScanner change date
November 17, 2026
Cited source date
April 15, 2016
Evidence lane
Regulatory
Record added

Federal Register notice 2018-15735

The Federal Register published notice 2018-15735, attributed to FDA and its parent HHS department, on 2018-07-23. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.

PeptideScanner change date
November 17, 2026
Cited source date
July 23, 2018
Evidence lane
Regulatory
Record added

ClinicalTrials.gov record NCT00078338

PeptideScanner retained ClinicalTrials.gov record NCT00078338 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-27, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
June 27, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00176592

PeptideScanner retained ClinicalTrials.gov record NCT00176592 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-11-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00203021

PeptideScanner retained ClinicalTrials.gov record NCT00203021 at 2026-11-16T17:42:50.457Z. Its registry update date was 2020-02-18, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
February 18, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00211887

PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
April 3, 2014
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00239993

PeptideScanner retained ClinicalTrials.gov record NCT00239993 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
February 6, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00337779

PeptideScanner retained ClinicalTrials.gov record NCT00337779 at 2026-11-16T17:42:50.457Z. Its registry update date was 2011-10-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
October 10, 2011
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00451204

PeptideScanner retained ClinicalTrials.gov record NCT00451204 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-06-16, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
June 16, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00451451

PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
January 26, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00475865

PeptideScanner retained ClinicalTrials.gov record NCT00475865 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-11-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
November 6, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00666224

PeptideScanner retained ClinicalTrials.gov record NCT00666224 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-06-25, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
June 25, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00811395

PeptideScanner retained ClinicalTrials.gov record NCT00811395 at 2026-11-16T17:42:50.457Z. Its registry update date was 2012-12-31, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
December 31, 2012
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00856635

PeptideScanner retained ClinicalTrials.gov record NCT00856635 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-02-06, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
February 6, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00937157

PeptideScanner retained ClinicalTrials.gov record NCT00937157 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-03-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
March 19, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00947752

PeptideScanner retained ClinicalTrials.gov record NCT00947752 at 2026-11-16T17:42:50.457Z. Its registry update date was 2017-03-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
March 14, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01067521

PeptideScanner retained ClinicalTrials.gov record NCT01067521 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
December 9, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01071083

PeptideScanner retained ClinicalTrials.gov record NCT01071083 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-09-19, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
September 19, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01167426

PeptideScanner retained ClinicalTrials.gov record NCT01167426 at 2026-11-16T17:42:50.457Z. Its registry update date was 2013-10-17, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
October 17, 2013
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01216072

PeptideScanner retained ClinicalTrials.gov record NCT01216072 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-02-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
February 10, 2014
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01317004

PeptideScanner retained ClinicalTrials.gov record NCT01317004 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-06-22, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
June 22, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01534182

PeptideScanner retained ClinicalTrials.gov record NCT01534182 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-08-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
August 8, 2014
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01569451

PeptideScanner retained ClinicalTrials.gov record NCT01569451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-06-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
June 8, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT01874145

PeptideScanner retained ClinicalTrials.gov record NCT01874145 at 2026-11-16T17:42:50.457Z. Its registry update date was 2016-01-14, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
January 14, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02153723

PeptideScanner retained ClinicalTrials.gov record NCT02153723 at 2026-11-16T17:42:50.457Z. Its registry update date was 2018-11-05, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
November 5, 2018
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT02499900

PeptideScanner retained ClinicalTrials.gov record NCT02499900 at 2026-11-16T17:42:50.457Z. Its registry update date was 2021-12-09, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
December 9, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03193866

PeptideScanner retained ClinicalTrials.gov record NCT03193866 at 2026-11-16T17:42:50.457Z. Its registry update date was 2025-04-20, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.

PeptideScanner change date
November 16, 2026
Cited source date
April 20, 2025
Evidence lane
Clinical trials
Record added

Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

PubMed lists PMID 22449210 in Expert review of neurotherapeutics as Journal Article, Review, with publication-date metadata of 2012-04 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 19, 2015
Evidence lane
Literature metadata
Record added

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.

PubMed lists PMID 22989378 in BMC neurology as Controlled Clinical Trial, Journal Article, with publication-date metadata of 2012-09-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
April 8, 2022
Evidence lane
Literature metadata
Record added

Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

PubMed lists PMID 23203082 in International journal of molecular sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2012-11-09 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
May 5, 2024
Evidence lane
Literature metadata
Record added

Interferon beta and glatiramer acetate therapy.

PubMed lists PMID 23264098 in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2013-01 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
February 4, 2024
Evidence lane
Literature metadata
Record added

Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

PubMed lists PMID 23424159 in Annals of neurology as Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, with publication-date metadata of 2013-03-11 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
May 18, 2026
Evidence lane
Literature metadata
Record added

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.

PubMed lists PMID 23589190 in Journal of neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-04-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
October 21, 2021
Evidence lane
Literature metadata
Record added

The use of interferon Beta and glatiramer acetate in multiple sclerosis.

PubMed lists PMID 23709209 in Seminars in neurology as Journal Article, Review, with publication-date metadata of 2013-05-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 19, 2015
Evidence lane
Literature metadata
Record added

The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment.

PubMed lists PMID 23795716 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2013-06-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
April 8, 2022
Evidence lane
Literature metadata
Record added

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

PubMed lists PMID 25062935 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2014-07-26 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 28, 2025
Evidence lane
Literature metadata
Record added

Spasticity in multiple sclerosis and role of glatiramer acetate treatment.

PubMed lists PMID 26445705 in Brain and behavior as Journal Article, Review, with publication-date metadata of 2015-07-14 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 13, 2018
Evidence lane
Literature metadata
Record added

Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.

PubMed lists PMID 26458034 in JAMA neurology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-12 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
March 30, 2022
Evidence lane
Literature metadata
Record added

Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).

PubMed lists PMID 26671082 in Journal of the neurological sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-08 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
December 16, 2015
Evidence lane
Literature metadata
Record added

Pharmacologic Treatment of Rett Syndrome With Glatiramer Acetate.

PubMed lists PMID 27363291 in Pediatric neurology as Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2016-05-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
May 15, 2018
Evidence lane
Literature metadata
Record added

MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.

PubMed lists PMID 27473139 in Neurology as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2016-07-29 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
November 13, 2018
Evidence lane
Literature metadata
Record added

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

PubMed lists PMID 27880972 in The Cochrane database of systematic reviews as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2016-11-24 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
September 6, 2026
Evidence lane
Literature metadata
Record added

Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.

PubMed lists PMID 29241378 in Expert opinion on drug delivery as Journal Article, Review, with publication-date metadata of 2017-12-22 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 22, 2019
Evidence lane
Literature metadata
Record added

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use.

PubMed lists PMID 30775037 in Multiple sclerosis international as Journal Article, Review, with publication-date metadata of 2019-01-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
September 29, 2020
Evidence lane
Literature metadata
Record added

Glatiramer acetate: A complex drug beyond biologics.

PubMed lists PMID 30902653 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Journal Article, Review, with publication-date metadata of 2019-03-19 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
August 15, 2019
Evidence lane
Literature metadata
Record added

Glatiramer Acetate: from Bench to Bed and Back.

PubMed lists PMID 30905097 in The Israel Medical Association journal : IMAJ as Journal Article, Review, with publication-date metadata of 2019-03 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
April 1, 2019
Evidence lane
Literature metadata
Record added

Comparison of Copaxone® and Synthon's therapeutically equivalent glatiramer acetate.

PubMed lists PMID 31526436 in Die Pharmazie as Journal Article, Review, with publication-date metadata of 2019-08-01 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
June 11, 2020
Evidence lane
Literature metadata
Record added

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial.

PubMed lists PMID 32897569 in Acta neurologica Scandinavica as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2020-10-27 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 19, 2021
Evidence lane
Literature metadata
Record added

Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?

PubMed lists PMID 35493825 in Frontiers in neurology as Journal Article, Review, with publication-date metadata of 2022-04-15 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 16, 2022
Evidence lane
Literature metadata
Record added

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.

PubMed lists PMID 35563884 in Cells as Journal Article, Systematic Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, with publication-date metadata of 2022-05-07 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
June 23, 2025
Evidence lane
Literature metadata
Record added

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair.

PubMed lists PMID 39406508 in Pharmacological reviews as Journal Article, Review, with publication-date metadata of 2024-10-16 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
May 21, 2026
Evidence lane
Literature metadata
Record added

GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial.

PubMed lists PMID 41705515 in Multiple sclerosis (Houndmills, Basingstoke, England) as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
July 21, 2026
Evidence lane
Literature metadata